Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.
The aim of this study was to investigate the therapeutic efficacy of 211At-labelled monoclonal antibody given intraperitoneally to nude mice with intraperitoneal growth of a human ovarian cancer cell line. Female nude mice were inoculated intraperitoneally with 1 x 10(7) cells of the human ovarian cancer cell line NIH:OVCAR 3. After about two weeks they were injected with the 211At-labelled specific monoclonal antibody MOv18 intraperitoneally. For comparison, other groups of mice were given the same labelled antibody intravenously, 211At-labelled unspecific antibody C242 intraperitoneally or unalbelled MOv18 intraperitoneally. Six weeks later the animals were sacrificed and the occurrence of tumour and ascites was determined. When the mice were treated with 211At-labelled MOv18 intraperitoneally 9 out of 10 were apparently free of both ascites and tumour compared to none of the mice given unlabelled antibody. 211At-labelled MOv18 given intravenously or 211At-labelled unspecific antibody given intraperitoneally were less effective. Regional radioimmunotherapy with the alpa-emitter 211Astatine seems to be an effective treatment of nude mice with intraperitoneally growing human ovarian cancer. Hopefully this treatment can be given in an adjuvant setting to women with minimal residual ovarian cancer in the future.
Andersson
H
H
Department of Gynecological Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Lindegren
S
S
Back
T
T
Jacobsson
L
L
Leser
G
G
Horvath
G
G
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000008:administration & dosage / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology; D001201:Ascites / Q000209:etiology / Q000532:radiotherapy; D001246:Astatine / Q000008:administration & dosage / Q000627:therapeutic use*; D002277:Carcinoma / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy*; D002352:Carrier Proteins / Q000276:immunology; D005260:Female; D058973:Folate Receptors, GPI-Anchored; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008562:Membrane Glycoproteins / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009363:Neoplasm Proteins / Q000276:immunology; D009368:Neoplasm Transplantation; D018365:Neoplasm, Residual; D010051:Ovarian Neoplasms / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy*; D010534:Peritoneal Neoplasms / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy*; D016499:Radioimmunotherapy; D011956:Receptors, Cell Surface; D014183:Transplantation, Heterologous
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D002352:Carrier Proteins; D058973:Folate Receptors, GPI-Anchored; D018796:Immunoconjugates; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; D011956:Receptors, Cell Surface; D001246:Astatine